UBI Stock Overview
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Universal Biosensors, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.16 |
| 52 Week High | AU$0.31 |
| 52 Week Low | AU$0.14 |
| Beta | 0.94 |
| 1 Month Change | -15.79% |
| 3 Month Change | -8.57% |
| 1 Year Change | -38.46% |
| 3 Year Change | -77.14% |
| 5 Year Change | -27.27% |
| Change since IPO | -56.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| UBI | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 3.2% | -0.2% | 0.7% |
| 1Y | -38.5% | 15.5% | 6.3% |
Return vs Industry: UBI underperformed the Australian Medical Equipment industry which returned 15.5% over the past year.
Return vs Market: UBI underperformed the Australian Market which returned 6.3% over the past year.
Price Volatility
| UBI volatility | |
|---|---|
| UBI Average Weekly Movement | 21.3% |
| Medical Equipment Industry Average Movement | 9.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: UBI's share price has been volatile over the past 3 months.
Volatility Over Time: UBI's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 80 | John Sharman | www.universalbiosensors.com |
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also offers non-diagnostic laboratory services and performs coagulation testing services.
Universal Biosensors, Inc. Fundamentals Summary
| UBI fundamental statistics | |
|---|---|
| Market cap | AU$35.87m |
| Earnings (TTM) | -AU$6.39m |
| Revenue (TTM) | AU$6.81m |
5.3x
P/S Ratio-5.6x
P/E RatioIs UBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UBI income statement (TTM) | |
|---|---|
| Revenue | AU$6.81m |
| Cost of Revenue | AU$2.52m |
| Gross Profit | AU$4.29m |
| Other Expenses | AU$10.68m |
| Earnings | -AU$6.39m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 62.97% |
| Net Profit Margin | -93.90% |
| Debt/Equity Ratio | 3.3% |
How did UBI perform over the long term?
See historical performance and comparison